-
Tomivosertib Suppresses Human DRG Ectopic Activity in Radicu
2026-06-11
This study directly demonstrates that tomivosertib, a selective MNK inhibitor, rapidly and reversibly reduces spontaneous activity in human dorsal root ganglion neurons from radiculopathy patients. The findings provide first-in-human evidence that targeting MNK signaling may offer a promising therapeutic strategy for neuropathic pain, with implications for translational research on peripheral pain mechanisms.
-
Toxicology of 5-Aza-2'-deoxycytidine: Insights from Mouse Mo
2026-06-11
The foundational study by Momparler and Frith systematically examines the acute and reversible toxic effects of 5-Aza-2'-deoxycytidine (Decitabine) in mice, providing essential dose-limiting data for preclinical hematopoietic malignancy research. These findings inform translational strategies in cancer epigenetics by clarifying both the risks and recovery profiles associated with DNA hypomethylation therapy.
-
KG-501: Mechanism, Protocols, and Evidence in CREB Disruptio
2026-06-10
KG-501 is a selective small-molecule inhibitor of CREB-mediated transcription, acting by disrupting critical coactivator interactions. It demonstrates low micromolar potency, influences macrophage polarization, and is widely used to interrogate oncogenic and epigenetic pathways. This article consolidates mechanistic and protocol data for KG-501, referencing both peer-reviewed and product documentation.
-
Mitochondrial Calcium Signaling Represses Ferroptosis via GP
2026-06-10
This study reveals that mitochondrial calcium uptake, mediated by the mitochondrial calcium uniporter (MCU), is essential for repressing ferroptotic cell death through the regulation of GPX4 acetylation. The findings establish a direct mechanistic link between mitochondrial calcium signaling, acetyl-CoA metabolism, and ferroptosis resistance, offering new insights for therapeutic strategies targeting iron-dependent cell death.
-
Targeting β-Catenin/BCL9 Overcomes Immunotherapy Resistance
2026-06-09
Feng et al. introduce a novel approach for overcoming resistance to immune checkpoint blockade therapies by pharmacologically disrupting the β-catenin/BCL9 interaction. Their findings reveal that selective inhibition of this protein-protein interface modulates the tumor immune microenvironment, sensitizing resistant tumors to PD-1 blockade through effects on regulatory T cells and dendritic cells.
-
Cucurbitacin I (JSI-124): STAT3 Inhibition in Tumor Models
2026-06-09
Cucurbitacin I (JSI-124) offers precise and selective STAT3 pathway inhibition, enabling reproducible studies of cancer cell proliferation, invasion, and therapeutic response. This guide details optimized experimental workflows and troubleshooting strategies, highlighting APExBIO’s trusted supply and the latest advances in complex human in vitro modeling.
-
Spleen-Targeted Neoantigen mRNA Vaccine Drives HCC Immunity
2026-06-08
Lin et al. developed a spleen-targeted neoantigen mRNA vaccine (STNvac) that significantly enhances antitumor immunity in hepatocellular carcinoma (HCC) by inducing ISG15+ CD8+ T cells and promoting tertiary lymphoid structure (TLS) formation. This study establishes the mechanistic foundation for improved mRNA vaccine design in immunologically resistant tumors.
-
Epalrestat-Induced KEAP1/Nrf2 Activation in Parkinson’s Mode
2026-06-08
Jia et al. (2025) demonstrate that Epalrestat, a clinically used aldose reductase inhibitor, exerts neuroprotective effects in Parkinson’s disease models by directly binding to KEAP1 and activating the Nrf2 antioxidant pathway. Their findings provide mechanistic insight into Epalrestat’s potential to attenuate oxidative stress and dopaminergic neuron loss, supporting its repurposing for neurodegenerative disease research.
-
Applied Workflows with Recombinant Mouse Macrophage Colony S
2026-06-07
Harnessing high-purity Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag from APExBIO unlocks reproducible macrophage-driven disease models. This guide translates bench research into actionable workflows for macrophage activation, osteoclast assays, and fibrosis studies, with protocol optimizations and troubleshooting rooted in the latest mechanistic discoveries.
-
Epalrestat Activates KEAP1/Nrf2 for Neuroprotection in Parki
2026-06-06
Jia et al. (2025) demonstrate that epalrestat, a clinically approved aldose reductase inhibitor, confers neuroprotection in Parkinson’s disease models by directly binding KEAP1 and activating the Nrf2 pathway. This finding clarifies the molecular mechanism behind epalrestat’s antioxidant effects and suggests new directions for research on disease-modifying therapies in neurodegeneration.
-
6-Thioguanine Suppresses EV71 via BIRC3-Mediated Autophagy I
2026-06-05
The referenced study establishes 6-thioguanine as a potent inhibitor of Enterovirus 71 (EV71) replication through suppression of BIRC3-mediated autophagy in vitro. These mechanistic insights position 6-thioguanine as a promising candidate for antiviral intervention in hand, foot, and mouth disease (HFMD), with translational implications for virology research.
-
Next-Gen Immunogen mRNA: Mechanisms, Delivery, and Translati
2026-06-05
This article explores the strategic and mechanistic landscape of immunogen mRNA—focusing on EZ Cap™ OVA mRNA—as a platform for immune response modeling, gene expression, and vaccine development. By synthesizing recent advances in low-inflammation mRNA delivery, it provides actionable guidance for translational researchers seeking to optimize preclinical and clinical workflows.
-
Enhancing mRNA Assays: N1-Methylpseudouridine (SKU B8340) in
2026-06-04
This article delivers a scenario-driven guide for biomedical researchers and lab technicians seeking to optimize cell viability and protein expression assays with N1-Methylpseudouridine (SKU B8340). Drawing on validated product data and benchmark literature, we address common workflow challenges—highlighting how this modified nucleoside from APExBIO provides reproducible mRNA translation enhancement and reduced immunogenicity. Practical Q&A blocks, protocol tips, and cross-domain insights empower evidence-based experimental design.
-
HA-SiRNA Nanoparticles Target TDRD9 to Reduce P. aeruginosa
2026-06-04
This study develops hyaluronic acid sodium salt-coated siRNA nanoparticles targeting Tudor domain-containing protein 9 (TDRD9) in neutrophils, demonstrating that modulation of neutrophil cuproptosis alleviates Pseudomonas aeruginosa-induced lung injury in preclinical models. The findings establish a novel approach for immune modulation in bacterial pneumonia and highlight the translational potential of ECM-inspired delivery platforms.
-
EZ Cap™ OVA mRNA: Enhancing Immune Research & mRNA Delivery
2026-06-03
EZ Cap™ OVA mRNA delivers consistent, high-purity ovalbumin transcripts with precise Cap 1 capping for immunology and vaccine development workflows. This article details actionable protocols, advanced use-cases, and troubleshooting strategies, tying in the latest delivery innovations for optimal immune response modeling.